On November 10, 2022, the NRC issued a notice of violation to NukeMed Inc., dba SpectronRx (licensee) for a Severity Level III violation. The violation involved the licensee’s failure to confine its possession of material to what is approved on its NRC license, as required by Title 10 of the Code of Federal Regulations Part 30.3(a).